Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Cause of Alzheimer’s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress
Boris Decourt, Gary X. D’Souza, Jiong Shi, et al.
Aging and Disease (2022) Vol. 13, Iss. 1, pp. 37-37
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Role of Environmental Toxicants on Neurodegenerative Disorders
Masarat Nabi, Nahida Tabassum
Frontiers in Toxicology (2022) Vol. 4
Open Access | Times Cited: 104
Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease
Grace Vitek, Boris Decourt, Marwan N. Sabbagh
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 2, pp. 89-94
Closed Access | Times Cited: 55
Quercetin-functionalized nanomaterials: Innovative therapeutic avenues for Alzheimer's disease management
Jinjin Pei, Ranil Vikraman Kumarasamy, Selvaraj Jayaraman, et al.
Ageing Research Reviews (2025), pp. 102665-102665
Closed Access | Times Cited: 3
Roles of Ependymal Cells in the Physiology and Pathology of the Central Nervous System
Shiyu Deng, Lin Gan, Chang Liu, et al.
Aging and Disease (2022)
Open Access | Times Cited: 43
Cognitive disorders in patients with chronic kidney disease: Approaches to prevention and treatment
Marion Pépin, Aleksandra Klimkowicz‐Mrowiec, Olivier Godefroy, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 9, pp. 2899-2911
Open Access | Times Cited: 26
Beneficial effects of physical exercise on cognitive-behavioral impairments and brain-derived neurotrophic factor alteration in the limbic system induced by neurodegeneration
Farhad Sanaeifar, Sina Pourranjbar, Mohammad Pourranjbar, et al.
Experimental Gerontology (2024) Vol. 195, pp. 112539-112539
Open Access | Times Cited: 10
Red blood cells as biomarkers and mediators in complications of diabetes mellitus: A review
Emmanuel Ifeanyi Obeagu
Medicine (2024) Vol. 103, Iss. 8, pp. e37265-e37265
Open Access | Times Cited: 5
Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia
Boris Decourt, Keith Noorda, Kevin Noorda, et al.
Journal of Experimental Pharmacology (2022) Vol. Volume 14, pp. 331-352
Open Access | Times Cited: 20
COR388 (atuzaginstat): an investigational gingipain inhibitor for the treatment of Alzheimer disease
Marwan N. Sabbagh, Boris Decourt
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 10, pp. 987-993
Open Access | Times Cited: 19
Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications
Sarrah E Ankeny, Julia R Bacci, Boris Decourt, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 6, pp. 1541-1557
Open Access | Times Cited: 4
Microvascular dysfunction in a murine model of Alzheimer’s disease using intravital microscopy
Danielle Sidsworth, Noah Tregobov, Colin Jamieson, et al.
Frontiers in Aging Neuroscience (2025) Vol. 17
Open Access
Reduced levels of angiogenesis biomarkers predict increased symptom severity in Chinese Americans with Alzheimer’s disease with demographic-specific effect
Taylor P. Johnson, Elena Tsoy, Jeffrey Shen, et al.
Neurocase (2025), pp. 1-10
Closed Access
The Impact of the Exposome on Alzheimer’s Disease: The Influence of Nutrition
Martina Monaco, Carola Torazza, Ernesto Fedele, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3015-3015
Open Access
Cholesterol-modifying strategies for alzheimer disease: promise or fallacy?
Katia Azarfar, Boris Decourt, Bernardo León Camacho, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Role of Pyrazole Moiety in the Treatment of Alzheimer's Disease: A Comprehensive Review of Various Synthetic Routes and Probable Mechanisms of Action
Aman Thakur, Ranjit Singh, Vineet Mehta, et al.
ChemistrySelect (2025) Vol. 10, Iss. 13
Closed Access
Analysis of cognitive status of Alzheimer’s disease’s subjects and its association with biomarkers (amyloid beta and tau proteins) using NACC data
Vaghawan Prasad Ojha, Sudeh Riahi, Richard Hunt Bobo, et al.
Discover Psychology (2025) Vol. 5, Iss. 1
Open Access
Amyloid-Directed Antibodies: Past, Present, and Future
Keith Noorda, Kevin Noorda, Marwan N. Sabbagh, et al.
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S3-S22
Closed Access | Times Cited: 3
Discovery of novel multifunctional ligands targeting GABA transporters, butyrylcholinesterase, β-secretase, and amyloid β aggregation as potential treatment of Alzheimer's disease
Paula Zaręba, Kamil Łątka, Gabriela Mazur, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115832-115832
Open Access | Times Cited: 8
Biomarker-based diagnosis of preclinical Alzheimer disease: time for the clinic?
Marwan N. Sabbagh, Boris Decourt
Nature Reviews Neurology (2023) Vol. 19, Iss. 2, pp. 71-72
Open Access | Times Cited: 7
Potential for Ketotherapies as Amyloid-Regulating Treatment in Individuals at Risk for Alzheimer’s Disease
Matthew Taylor, Debra K. Sullivan, Jessica Keller, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 12
Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the σ1 chaperone protein
Laura García-Pupo, Lucie Crouzier, Alberto Bencomo-Martínez, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4345-4359
Open Access | Times Cited: 2
EEG and ERP biosignatures of mild cognitive impairment for longitudinal monitoring of early cognitive decline in Alzheimer’s disease
Amir H. Meghdadi, David H. Salat, Joanne M. Hamilton, et al.
PLoS ONE (2024) Vol. 19, Iss. 8, pp. e0308137-e0308137
Open Access | Times Cited: 2
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
A. Wicker, Jahnavi Shriram, Boris Decourt, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 6, pp. 1571-1595
Open Access | Times Cited: 2
QEEG Signatures are Associated with Nonmotor Dysfunctions in Parkinson's Disease and Atypical Parkinsonism: An Integrative Analysis
Hailing Liu, Zifeng Huang, Bin Deng, et al.
Aging and Disease (2022) Vol. 14, Iss. 1, pp. 204-204
Open Access | Times Cited: 10
The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators
Hans J. Moebius, Kevin J. Church
Journal of Alzheimer s Disease (2023) Vol. 92, Iss. 1, pp. 1-12
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top